ArticleAllergy2021
Laser-facilitated epicutaneous immunotherapy with hypoallergenic beta-glucan neoglycoconjugates suppresses lung inflammation and avoids local side effects in a mouse model of allergic asthma.
Article in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Dendritic cells as orchestrators in the allergen-specific immunotherapy of allergic diseases.Clinical reviews in allergy & immunology · 2026Review
- β-glucan nanoparticles alleviate acute asthma by suppressing ferroptosis and DNA damage in mice.Apoptosis : an international journal on programmed cell death · 2025Article
- WISIT vaccines based on IL-31-derived peptides as a novel therapeutic approach for chronic pruritic dermatoses.PloS one · 2025Article
- An epicutaneous therapeutic pollen-allergen extract delivery system in an allergic rhinitis mouse model: based on allergen loading on DC-specific aptamers conjugated nanogolds.Immunologic research · 2024Article
- NLRP3 promotes allergic responses to birch pollen extract in a model of intranasal sensitization.Frontiers in immunology · 2024Article
- C-Type Lectin Receptor Mediated Modulation of T2 Immune Responses to Allergens.Current allergy and asthma reports · 2023Review
- Innovative delivery systems for epicutaneous immunotherapy.Frontiers in immunology · 2023Review
- Recent advances in epicutaneous immunotherapy and potential applications in food allergy.Frontiers in allergy · 2023Review
- Mechanisms and biomarkers of successful allergen-specific immunotherapy.Asia Pacific allergy · 2022Review
- Article
- Article
- Article
- Enhancement of β-Glucan Biological Activity Using a Modified Acid-Base Extraction Method fromMolecules (Basel, Switzerland) · 2021Article
- Article
- The Role of Regulatory T Cells in Epicutaneous Immunotherapy for Food Allergy.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergen-specific immunotherapy via the skin targets a tissue rich in antigen-presenting cells, but can be associated with local and systemic side effects. Allergen-polysaccharide neoglycogonjugates increase immunization efficacy by targeting and activating dendritic cells via C-type lectin receptors and reduce side effects.
objectiveWe investigated the immunogenicity, allergenicity, and therapeutic efficacy of laminarin-ovalbumin neoglycoconjugates (LamOVA).
methodsThe biological activity of LamOVA was characterized in vitro using bone marrow-derived dendritic cells. Immunogenicity and therapeutic efficacy were analyzed in BALB/c mice. Epicutaneous immunotherapy (EPIT) was performed using fractional infrared laser ablation to generate micropores in the skin, and the effects of LamOVA on blocking IgG, IgE, cellular composition of BAL, lung, and spleen, lung function, and T-cell polarization were assessed.
resultsConjugation of laminarin to ovalbumin reduced its IgE binding capacity fivefold and increased its immunogenicity threefold in terms of IgG generation. EPIT with LamOVA induced significantly higher IgG levels than OVA, matching the levels induced by s.c. injection of OVA/alum (SCIT). EPIT was equally effective as SCIT in terms of blocking IgG induction and suppression of lung inflammation and airway hyperresponsiveness, but SCIT was associated with higher levels of therapy-induced IgE and TH2 cytokines. EPIT with LamOVA induced significantly lower local skin reactions during therapy compared to unconjugated OVA.
conclusionConjugation of ovalbumin to laminarin increased its immunogenicity while at the same time reducing local side effects. LamOVA EPIT via laser-generated micropores is safe and equally effective compared to SCIT with alum, without the need for adjuvant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.